In the past week, VKTX stock has gone up by 11.85%, with a monthly gain of 9.62% and a quarterly surge of 31.03%. The volatility ratio for the week is 5.65%, and the volatility levels for the last 30 days are 6.11% for Viking Therapeutics Inc The simple moving average for the past 20 days is 8.61% for VKTX’s stock, with a -24.94% simple moving average for the past 200 days.
Is It Worth Investing in Viking Therapeutics Inc (NASDAQ: VKTX) Right Now?
The 36-month beta value for VKTX is at 0.66. Analysts have varying views on the stock, with 10 analysts rating it as a “buy”, 7 rating it as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for VKTX is 108.96M, and currently, shorts hold a 26.13% of that float. The average trading volume for VKTX on July 08, 2025 was 3.80M shares.
VKTX stock’s latest price update
The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) has surged by 7.74% when compared to previous closing price of $27.51, but the company has seen a 11.85% gain in its stock price over the last five trading sessions. fool.com reported 2025-07-07 that Though you may think “tech stocks” when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for explosive growth.
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with Cantor Fitzgerald repeating the rating for VKTX by listing it as a “Overweight”. The predicted price for VKTX in the upcoming period, according to Cantor Fitzgerald is $104 based on the research report published on April 29, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $30. The rating they have provided for VKTX stocks is “Neutral” according to the report published on April 08th, 2025.
Citigroup gave a rating of “Neutral” to VKTX, setting the target price at $38 in the report published on February 07th of the current year.
VKTX Trading at 8.06% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.73% of loss for the given period.
Volatility was left at 6.11%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares surge +4.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.68% upper at present.
During the last 5 trading sessions, VKTX rose by +10.08%, which changed the moving average for the period of 200-days by -53.65% in comparison to the 20-day moving average, which settled at $27.27. In addition, Viking Therapeutics Inc saw -41.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from Lian Brian, who sold 26,889 shares at the price of $27.80 back on Jul 03 ’25. After this action, Lian Brian now owns 2,388,014 shares of Viking Therapeutics Inc, valued at $747,633 using the latest closing price.
ZANTE GREG, the Chief Financial Officer of Viking Therapeutics Inc, sale 4,266 shares at $27.76 during a trade that took place back on Jul 03 ’25, which means that ZANTE GREG is holding 168,660 shares at $118,428 based on the most recent closing price.
Stock Fundamentals for VKTX
The total capital return value is set at -0.2%. Equity return is now at value -14.40%, with -13.98% for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -133.99. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -2610.86.
Currently, EBITDA for the company is -109.52 million with net debt to EBITDA at 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 44.25.
Conclusion
In conclusion, Viking Therapeutics Inc (VKTX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
